Regulating ILC2 activity, particularly through factors like Regnase‐1 and IFN‐γ signaling, represents a potential therapeutic target for mitigating fibrosis in patients with IPF. The gene discussed is IFNG; the disease is idiopathic pulmonary fibrosis.